Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.

Abubaker K, Luwor RB, Escalona R, McNally O, Quinn MA, Thompson EW, Findlay JK, Ahmed N.

Front Oncol. 2014 Apr 9;4:75. doi: 10.3389/fonc.2014.00075. eCollection 2014.

PMID:
24782986
[PubMed]
Free PMC Article
2.

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.

Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N.

BMC Cancer. 2014 May 6;14:317. doi: 10.1186/1471-2407-14-317.

PMID:
24886434
[PubMed - in process]
Free PMC Article
3.

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.

Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, Thompson EW, Findlay JK, Ahmed N.

Mol Cancer. 2013 Mar 27;12:24. doi: 10.1186/1476-4598-12-24.

PMID:
23537295
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB.

Cancer Res. 2002 Feb 15;62(4):1087-92.

PMID:
11861387
[PubMed - indexed for MEDLINE]
Free Article
5.

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.

Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB.

Am J Pathol. 2002 Nov;161(5):1917-24.

PMID:
12414537
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo.

Kandala PK, Srivastava SK.

Drug Discov Ther. 2012 Apr;6(2):94-101.

PMID:
22622019
[PubMed - indexed for MEDLINE]
Free Article
7.

The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.

Clin Cancer Res. 2003 Aug 15;9(9):3476-85.

PMID:
12960140
[PubMed - indexed for MEDLINE]
Free Article
8.

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Feb;15(2):198-207. doi: 10.1093/neuonc/nos302. Epub 2012 Dec 21.

PMID:
23262510
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.

Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV.

Clin Cancer Res. 2006 Sep 1;12(17):5055-63.

PMID:
16951221
[PubMed - indexed for MEDLINE]
Free Article
10.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

PMID:
17938703
[PubMed]
Free PMC Article
11.

Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin.

Colomiere M, Findlay J, Ackland L, Ahmed N.

Int J Biochem Cell Biol. 2009 May;41(5):1034-45. doi: 10.1016/j.biocel.2008.09.018. Epub 2008 Sep 27.

PMID:
18930836
[PubMed - indexed for MEDLINE]
12.

In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo.

Okugawa K, Kobayashi H, Hirakawa T, Sonoda T, Ogura T, Nakano H.

J Cancer Res Clin Oncol. 2004 Mar;130(3):178-86. Epub 2003 Dec 4.

PMID:
14655049
[PubMed - indexed for MEDLINE]
13.

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.

Nguyen DM, Lorang D, Chen GA, Stewart JH 4th, Tabibi E, Schrump DS.

Ann Thorac Surg. 2001 Aug;72(2):371-8; discussion 378-9.

PMID:
11515869
[PubMed - indexed for MEDLINE]
14.

CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.

Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H, Seiden MV.

Cancer Chemother Pharmacol. 2009 Mar;63(4):681-9. doi: 10.1007/s00280-008-0785-8. Epub 2008 Jun 28.

PMID:
18587580
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.

Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A.

Mol Cancer Ther. 2007 Jul;6(7):2003-11.

PMID:
17620430
[PubMed - indexed for MEDLINE]
Free Article
16.

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N.

PLoS One. 2012;7(10):e46858. doi: 10.1371/journal.pone.0046858. Epub 2012 Oct 8.

PMID:
23056490
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.

Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV.

Mol Pharmacol. 2007 Nov;72(5):1137-45. Epub 2007 Aug 3.

PMID:
17675586
[PubMed - indexed for MEDLINE]
Free Article
18.

Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.

Ma L, Lai D, Liu T, Cheng W, Guo L.

Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):593-602. doi: 10.1093/abbs/gmq067. Epub 2010 Aug 12.

PMID:
20705681
[PubMed - indexed for MEDLINE]
19.

[Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].

Guo YQ, Lu P, Duan ZF, Zhang Z.

Zhonghua Fu Chan Ke Za Zhi. 2010 Nov;45(11):854-9. Chinese.

PMID:
21211286
[PubMed - indexed for MEDLINE]
20.

c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.

Chau WK, Ip CK, Mak AS, Lai HC, Wong AS.

Oncogene. 2013 May 30;32(22):2767-81. doi: 10.1038/onc.2012.290. Epub 2012 Jul 16.

PMID:
22797058
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk